O'Melveny Represents Pharmaron in its US$588 million Hong Kong IPO
November 28, 2019
FOR IMMEDIATE RELEASE
O’Melveny recently represented Pharmaron Beijing Co., Ltd. (Pharmaron) (300759.SZ and 3759.HK), in its approximately HK$4.6 billion (approximately US$588 million) dual primary listing and H share offering in Hong Kong.
Based in Beijing, Pharmaron is a leading fully integrated pharmaceutical R&D service platform serving China and overseas pharmaceutical companies. Pharmaron established a leading position in drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.
The Joint Sponsors for the IPO are Goldman Sachs (Asia) LLC, CLSA Capital Markets Limited, and Orient Capital (Hong Kong) Limited.
The O’Melveny team was led by partners Portia Ku, Ke Zhu, and Edwin Kwok, and the team included counsel Vincent Lin, associates Wendy Kan, Aaron Xin, Yuki Tsang, and Edward Poon, trainee solicitor Darryl Wan, and legal consultant Tiffany Liu. Counsel Wenting Yu and Adam Ajlouni, and associates Sydney Ryan and Ying Li also provided valuable assistance.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.
Contact:
Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com